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Serum Institut, Copenhagen, DenmarkAbstractThe European, multicentre, quarterly point-prevalence study of community-acquired diarrhoea (EUCODI) analysed stool samples received at
ten participating clinical microbiology laboratories (Austria, Finland, France, Germany, Greece, Ireland, Italy, Portugal, Romania, and the UK)
in 2014. On four speciﬁed days, each local laboratory submitted samples from 20 consecutive patients to the Austrian Study Centre for
further testing with the FilmArray GI Panel (BioFire Diagnostics, Salt Lake City, UT, USA). Of the 709 samples from as many patients
received, 325 (45.8%) tested negative, 268 (37.8%) yielded only one organism, and 116 (16.4%) yielded multiple organisms. Positivity
rates ranged from 41% (30 of 73 samples) in France to 74% (59 of 80 samples) in Romania. With the exception of Entamoeba histolytica
and Vibrio cholerae, all of the 22 targeted pathogens were detected at least once. Enteropathogenic Escherichia coli, Campylobacter species,
toxigenic Clostridium difﬁcile, enteroaggregative E. coli, norovirus and enterotoxigenic E. coli were the six most commonly detected
pathogens. When tested according to local protocols, seven of 128 positive samples (5.5%) yielded multiple organisms. Overall, the
FilmArray GI Panel detected at least one organism in 54.2% (384/709) of the samples, as compared with 18.1% (128/709) when testing
was performed with conventional techniques locally. This underlines the considerable potential of multiplex PCR to improve routine
stool diagnostics in community-acquired diarrhoea. Classic culture methods directed at the isolation of speciﬁc pathogens are increasingly
becoming second-line tools, being deployed when rapid molecular tests give positive results. This optimizes the yield from stool
examinations and dramatically improves the timeliness of diagnosis.
Clinical Microbiology and Infection © 2015 The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and
Infectious Diseases.
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E-mail: Franz.Allerberger@ages.atIntroductionData regarding the enteric pathogens responsible for community-
acquired diarrhoeal illness in Europe are scarce, and mostClinical Microbiology and Infection © 2015 The Authors. Published by El
This is an open access artipublished studies report single-country data [1–6]. Even when
diagnostic efforts are pursued aggressively, an agent cannot be
identiﬁed for almost half of diarrhoeal cases if conventional
methods, such as culture, enzyme immunoassay, or microscopy,
are relied on for the detection of enteropathogens, either because
the pathogen is not detected or because the aetiology is non-
infectious [7–11]. Numerous publications have already shown
the added value of molecular multiplex detection of enter-
opathogens in comparison with conventional methods [12–14].
We report the ﬁrst European, multicentre, cross-sectional quar-
terly point-prevalence study of community-acquired diarrhoeaClin Microbiol Infect 2015; 21: 719–728
sevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases
cle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
http://dx.doi.org/10.1016/j.cmi.2015.04.007
720 Clinical Microbiology and Infection, Volume 21 Number 8, August 2015 CMI(EUCODI) to determine the spectrum of possible pathogens in
acute community-acquired gastroenteritis using both conven-
tional laboratory techniques and a commercially available multi-
plex PCR-based system, in order to obtain insights into the
aetiology of enteropathogens in Europe.Materials and methodsSamples
Laboratories (one from each of ten European countries (Fig. 1))
were recruited to collect 20 stool samples each, on four days
in 2014 (15 January, 16 April, 16 July, and 15 October),
reﬂecting seasonal variation in disease incidence. Countries
were chosen to reﬂect a wide geographical and socio-economic
range. Laboratories in each country were identiﬁed pragmati-
cally on the basis of established links and willingness toFIG. 1. Proportion of positive samples and pathogens per sample by count
Romania, and the UK; overall positivity rate = 384/709; 54.2%).
Clinical Microbiology and Infection © 2015 The Authors. Published by Elsevier Ltd on behalf of
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/liceparticipate. All unformed faecal samples from outpatients or
inpatients (within 48 h of admission) of all ages admitted with
community-acquired acute gastroenteritis were eligible for in-
clusion. Second or subsequent samples from identical patients,
solid samples and samples with clinical histories suggesting non-
infectious causes of diarrhoea were excluded.
Microbiology
Samples were routinely tested at local laboratories according to
the individual laboratories’ standard operating procedures.
Thereafter, each local laboratory transferred 500-μL (or gram-
equivalent) aliquots into 2 mL of modiﬁed Cary–Blair medium
(LBM FecalSwabs; Copan Diagnostics, Murieta, CA, USA) for
transport via courier service to the central study laboratory in
Vienna, Austria. At the central study laboratory, all stool sam-
ples were tested with a development version of a commercially
available multiplex PCR system, the FilmArray GI Panel (BioFirery (Austria, Finland, France, Germany, Greece, Ireland, Italy, Portugal,
European Society of Clinical Microbiology and Infectious Diseases, CMI, 21, 719–728
nses/by-nc-nd/4.0/)
TABLE 1. Patient characteristics of samples received by round and overall
Characteristic
Round
Total p1 2 3 4
Female, n (%) 81 (51.6) 89 (49.4) 95 (49.0) 101 (56.7) 366 (51.6) 0.431
Median age (IQR) 36 (51) 37 (43) 46 (41) 47 (44) 41 (43) 0.954
<5 years, n (%) 26 (16.6) 27 (15.0) 22 (11.3) 33 (18.5) 108 (15.2) 0.261
5–59 years, n (%) 91 (58.0) 102 (56.7) 107 (55.2) 88 (49.4) 388 (54.7) 0.398
60 years, n (%) 40 (25.5) 51 (28.3) 65 (33.5) 57 (32.0) 213 (30.0) 0.355
Healthcare provider, n (%)
Community based 104 (66.2) 135 (75.0) 130 (67.0) 102 (57.3) 471 (66.4) 0.006
Outpatient hospital based 3 (1.91) 6 (3.3) 25 (12.9) 38 (21.4) 72 (10.2) <0.001
Inpatient hospital based 50 (31.9) 39 (21.7) 39 (20.1) 38 (21.4) 166 (23.4) 0.043
Antibiotic treatment, n (%) 11 (7.0) 21 (11.7) 12 (6.2) 18 (10.1) 62 (8.7) 0.21
Median days from sampling to analysis (IQR) 8 (3) 13 (7) 12 (7) 11 (7) 11 (7) <0.001
Positive samples, n (%) 81 (51.6) 98 (54.4) 102 (52.6) 103 (57.9) 384 (54.2) 0.579
Total, N 157 180 194 178 709
IQR, interquartile range.
CMI Spina et al. Spectrum of pathogens in acute gastroenteritis 721Diagnostics, Salt Lake City, UT, USA). This panel allows
simultaneous detection of 22 common diarrhoeal agents,
including bacteria, viruses, and protozoa (with a total of 1 h of
run time and approximately 2 min of preparation time), as
follows: bacteria—Campylobacter jejuni, Campylobacter coli,
Campylobacter upsaliensis, toxigenic Clostridium difﬁcile, Plesio-
monas shigelloides, Salmonella, Vibrio parahaemolyticus, Vibrio vul-
niﬁcus, Vibrio cholerae, Yersinia enterocolitica, enterotoxigenic
Escherichia coli (ETEC) (lt/st), enteropathogenic E. coli (EPEC),
Shiga toxin-producing E. coli (stx1/stx2, including E. coli O157),
Shigella/enteroinvasive E. coli, and enteroaggregative E. coli
(EAEC); viruses—adenovirus F40/41, astrovirus, norovirus GI/
GII, rotavirus A, and sapovirus (genogroups I, II, IV, and V); and
protozoa—Cryptosporidium, Cyclospora cayetanensis, Entamoeba
histolytica, and Giardia lamblia.
Demographic data
Standardized forms for each stool sample detailed the following
demographic data: age, sex, healthcare facility requesting testing
(outpatient hospital-based provider vs. inpatient hospital-based
provider vs. community-based provider), and receipt of anti-
microbial therapy (if known).
Statistical analysis
In univariate analyses, categorical variables were tested with the
chi-squared test, and one-way analysis of variance was used for
continuous variables. Statistical analyses were performed with
STATA version 13 (StataCorp, College Station, TX, USA).
Figures were created with Microsoft Excel 2010 and QGIS
version 2.0.1-Dufour.
Ethical approval
The ethics commission of the city of Vienna determined (ac-
cording to regulation EK 13-151-VK_NZ) that the study did not
require formal ethical review.Clinical Microbiology and Infection © 2015 The Authors. Published by Elsevier Ltd on behalf
This is an open access artiResultsA total of 709 samples were received from the ten participating
countries: Austria, 80 samples (11.3% of all samples); Finland,
80 (11.3%); France, 73 (10.3%); Germany, 63 (8.9%); Greece,
33 (4.7%); Ireland, 80 (11.3%); Italy, 80 (11.3%); Portugal, 68
(9.6%); Romania, 80 (11.3%); and the UK, 72 (10.2%). The
proportion of samples received per country did not vary
signiﬁcantly by round (p 0.752).
Table 1 shows patient characteristics for the samples
received; of 709 patients providing anonymized samples, the
median age was 41 years (inter-quartile range (IQR) 43 years),
366 (51.6%) were female and 388 (54.7%) were aged 5–59
years. The majority of samples were from community-based
healthcare providers (471 patients; 66.4%). A minority of pa-
tients (62; 8.7%) had received antibiotic treatment. Patients
providing samples did not differ signiﬁcantly in sex distribution,
age, or receipt of antibiotic therapy, or by round. The settings of
healthcare providers sending samples did differ signiﬁcantly be-
tween rounds, especially ‘outpatient hospital based’ (p < 0.001).
Results of the central study laboratory using the
FilmArray GI Panel
A total of 745 runs were needed to analyse all 709 samples on
the FilmArray GI Panel (data not shown). Failed attempts
(n = 36; 4.8%) were attributable to either software errors (ten
runs/36 fails; 27.8%) or loss of vacuum pressure in the pouches
(26 runs/36 fails; 72.2%). The median number of days between
sampling and testing at the central study laboratory was 11
(IQR 7 days).
The overall positivity rate was 384 positive samples among
709 specimens (54.2%), with similar rates in each round
(Table 1). Among the 709 samples that were screened, in 187 a
single bacterium was detected (26.4%), in 62 a single virusof European Society of Clinical Microbiology and Infectious Diseases, CMI, 21, 719–728
cle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
722 Clinical Microbiology and Infection, Volume 21 Number 8, August 2015 CMI(8.7%), and in 19 a single protozoan (2.7%); 116 (16.4%) con-
tained multiple pathogens. Fig. 1 shows the positivity rate by
participating country. Positivity rates ranged from 41% (30 of 73
samples) in France to 74% (59 of 80 samples) in Romania.
With the exception of Entamoeba histolytica and V. cholerae,
all of the 22 targeted pathogens were detected at least once. A
total of 555 potential pathogens were detected in the 384
positive samples; the overall frequency distributions and those
among multiple pathogen samples are shown in Fig. 2. EPEC,
Campylobacter, toxigenic C. difﬁcile, EAEC, norovirus and ETEC
were the most commonly detected pathogens. Detection of
enteric pathogens varied by age group. Fig. 3 shows, in partic-
ular, that C. difﬁcile and EPEC occurred more frequently in the
>60-year age group, whereas norovirus and EPEC were more
prevalent in the <5-year age group. Pathogens with signiﬁcant
prevalence differences by age group were as follows: C. difﬁcile
(p 0.010), Salmonella (p 0.005), adenovirus (p 0.007), norovirus
(p < 0.001), rotavirus (p < 0.001), and sapovirus (p < 0.001).
The frequency of bacteria, viruses and protozoa found by
sampling round (total pathogens = 555) varied by season: 15
January—73 bacterial, 36 viral and 12 protozoan agents; 16
April—93 bacterial, 32 viral and six protozoan agents; 16
July—127 bacterial, 22 viral and four protozoan agents; and 15
October—115 bacterial, 26 viral and 9 protozoan agents.
Bacteria were the most commonly occurring pathogens
(n = 408), and were more frequently present in summer (July),
whereas viruses and protozoa occurred more frequently in107 
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FIG. 2. Overall frequency distribution of pathogens detected and frequency
pathogens detected (total pathogens = 555). EAEC, enteroaggregative Esche
Escherichia coli; ETEC, enterotoxigenic Escherichia coli; STEC, Shiga toxin-prod
Clinical Microbiology and Infection © 2015 The Authors. Published by Elsevier Ltd on behalf of
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licewinter (January). However, none of these differences was found
to be statistically signiﬁcant.
In 116 of the 709 samples (16.4%; 30.2% of 384 positive
samples), multiple pathogens were detected. Patients with
multiple pathogens were more likely to be < 5 years of age (p
0.008) and be hospital outpatients (p 0.001) than those with a
negative sample or with a single-pathogen sample (Table 2). On
checking for statistical differences between single infection and
no pathogen detected in age groups and inpatients and out-
patients, the only signiﬁcant result was that those with a single
infection were less likely to be taking antibiotics than those with
no infection (p 0.038) (artefact resulting from the small
numbers taking antibiotics). On comparison of those who were
infected (any number) with those who were not, the former
were more likely to be aged <5 years (p 0.001), were more
likely to be community based (p 0.008), and were less likely to
be taking antibiotics (p 0.025).
The most commonly occurring co-infection was Campylo-
bacter with EPEC (eight samples; 6.9% of samples with multiple
infections and 2.1% of positive samples), followed by triple
infection with EAEC, EPEC, and ETEC (seven samples; 6.0% of
multiple infections and 1.8% of positive samples) (Table 3).
EPEC or EAEC was present in 98 of 116 (84%) samples with
multiple pathogens detected. Indeed, 85% of EAEC-positive
samples and 54% of EPEC-positive samples contained other
pathogens (Fig. 2). As seen in Fig. 1, samples from Romania
most frequently had multiple pathogens, including two samples19 18 17 17 
13 12 10 
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TABLE 2. Patient demographics comparing samples with
multiple pathogens and those without (N [ 709)
Characteristic
Multiple
pathogens
(n [ 116)
Single pathogen
or not detected
(n [ 593) p
Female, n (%) 61 (52.6) 305 (51.4) 0.82
Median age (IQR) 32 (47) 44 (43) 0.838
<5 years, n (%) 27 (23.3) 81 (13.7) 0.008
5–59 years, n (%) 66 (56.9) 322 (54.3) 0.607
60 years, n (%) 23 (19.8) 190 (32.0) 0.009
Healthcare provider, n (%)
Community based 72 (62.1) 399 (67.3) 0.277
Outpatient hospital based 22 (19.0) 50 (8.4) 0.001
Inpatient hospital based 22 (19.0) 144 (24.3) 0.216
Antibiotic treatment, n (%) 11 (9.5) 51 (8.6) 0.758
IQR, interquartile range.
CMI Spina et al. Spectrum of pathogens in acute gastroenteritis 723each containing ﬁve pathogens. One contained Campylobacter,
C. difﬁcile (toxin A/B), norovirus (GI/II), rotavirus A, and sap-
ovirus; the other contained C. difﬁcile (toxin A/B), EAEC, EPEC,
norovirus (GI/II), and sapovirus. Both of these samples were
from hospital outpatients. A further sample from Germany
contained ﬁve pathogens: C. difﬁcile (toxin A/B), EAEC, ETEC,
norovirus (GI/II), and rotavirus A.
The positive Vibrio result was in a sample from Austria, and
was due to V. parahaemolyticus; routinely seeded blood agar
plates had grown abundant oxidase-positive colonies (species
identiﬁcation conﬁrmed by the Austrian National Vibrio Refer-
ence Laboratory).Clinical Microbiology and Infection © 2015 The Authors. Published by Elsevier Ltd on behalf
This is an open access artiWith the exception of Romania (where toxigenic C. difﬁcile
was by far the most common pathogen; 13 of 25 Romanian
C. difﬁcile cases (52%) were aged >60 years), in all cases the
most commonly occurring pathogen was either EPEC or
Campylobacter (Fig. 4). EPEC was among the top three most
frequent pathogens for all participating countries. Campylobacter
was among the top ﬁve pathogens for all countries except
France, Germany, and Romania (where it was ninth, eighth, and
sixth, respectively). Toxigenic C. difﬁcile was among the top
three pathogens for all countries except Austria, Ireland, Italy,
and the UK. Norovirus, except in Romania and the UK, was
always among the top six pathogens. Sapovirus was in the top
ﬁve pathogens in Ireland and Italy, and in the UK, where sap-
ovirus occurred more frequently than norovirus. Additionally,
the UK had the highest frequency of Giardia lamblia, it being the
fourth most common pathogen. Ireland had a high frequency of
adenovirus, which was not noted elsewhere.
Results of the local laboratories using conventional
laboratory techniques
Of the 709 samples, 581 (81.9%) were negative when tested
according to the local laboratory protocols. Campylobacter was
the most common pathogen (56 samples; 7.9%), followed by
Salmonella, toxigenic C. difﬁcile, rotavirus, and norovirus (20
(2.8%), 17 (2.4%), 14 (2.0%), and ten (1.4%), respectively).
EPEC, the most common pathogen identiﬁed on the FilmArrayof European Society of Clinical Microbiology and Infectious Diseases, CMI, 21, 719–728
cle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
TABLE 3. Frequency of multiple pathogen combinations (displaying those with a frequency of ‡2) and proportion of total samples
with multiple pathogens detected (n [ 16 multiples/384 positive samples)
Pathogens Frequency of samples
Proportion of samples with
multiple pathogens Proportion of positive samples
Campylobacter species + EPEC 8 6.9 2.1
EAEC + EPEC + ETEC 7 6.0 1.8
EPEC + norovirus (GI/II) 4 3.5 1.0
EAEC + EIEC 3 2.6 0.8
EAEC + EPEC 3 2.6 0.8
EPEC + Giardia lamblia 3 2.6 0.8
Adenovirus (F40/41) + norovirus (GI/II) 2 1.7 0.5
Clostridium difﬁcile (toxin A/B) + adenovirus (F40/41) + sapovirus 2 1.7 0.5
C. difﬁcile (toxin A/B) + EPEC 2 1.7 0.5
C. difﬁcile (toxin A/B) + ETEC 2 1.7 0.5
C. difﬁcile (toxin A/B) + STEC 2 1.7 0.5
Campylobacter + C. difﬁcile (toxin A/B) 2 1.7 0.5
Campylobacter + C. difﬁcile (toxin A/B) + EPEC 2 1.7 0.5
Campylobacter + EAEC + EPEC 2 1.7 0.5
Campylobacter + STEC 2 1.7 0.5
EAEC + EPEC + ETEC + EIEC 2 1.7 0.5
EAEC + norovirus (GI/II) 2 1.7 0.5
EPEC + Cryptosporidium 2 1.7 0.5
EPEC + rotavirus A 2 1.7 0.5
ETEC + rotavirus A 2 1.7 0.5
STEC + norovirus (GI/II) 2 1.7 0.5
STEC + rotavirus A 2 1.7 0.5
Salmonella + EAEC 2 1.7 0.5
Salmonella + EPEC 2 1.7 0.5
Subtotal 64 55.2 17.7
Total multiple pathogens detected 116 100.0 30.2
EAEC, enteroaggregative Escherichia coli; EIEC, enteroinvasive E. coli; EPEC, enteropathogenic E. coli; ETEC, enterotoxigenic E. coli; STEC, Shiga toxin-producing E. coli.
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724 Clinical Microbiology and Infection, Volume 21 Number 8, August 2015 CMIGI Panel, was detected in only three samples (0.4%), and EAEC
was not detected in any. Only Germany, Italy and Romania
tested for EPEC, and none of the participating laboratories
tested for EAEC. Only seven samples contained two pathogens
(1.0%), with no combinations occurring more than once; four
of the seven contained a diarrhoeagenic E. coli. Fig. 5 shows the
results of the two diagnostic approaches for comparison.Clinical Microbiology and Infection © 2015 The Authors. Published by Elsevier Ltd on behalf of
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/liceDiscussionThe results of the EUCODI study impressively underline the
wide spectrum of possible enteric pathogens in patients with
community-acquired gastroenteritis: with the exception of
Entamoeba histolytica and V. cholerae, all of the 22 targetedEuropean Society of Clinical Microbiology and Infectious Diseases, CMI, 21, 719–728
nses/by-nc-nd/4.0/)
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CMI Spina et al. Spectrum of pathogens in acute gastroenteritis 725potential pathogens were detected at least once. This un-
derscores the importance of using a comprehensive test
spectrum for the work-up of samples from patients with
community-acquired gastroenteritis. In our European study,
the FilmArray GI Panel detected at least one organism in 54%
of the samples, whereas the local laboratory protocols
detected at least one organism in 18.1% of the samples. Data
from the manufacturer’s clinical trials in the USA had yielded a
nearly identical positivity rate: possible pathogens were
detected in 832 of 1556 patients (53.5%) [13]. Among 230
samples collected prospectively in 2013–2014 at the Mayo
Clinic in Rochester MN, 76 (33.0%) were positive for one or
more gastrointestinal (GI) pathogens by FilmArray GI Panel
testing vs. 8.3% by routine testing [14]. In Austria, stool
specimens submitted to a private laboratory and to the labo-
ratory of a university hospital for routine testing (e.g. culture,
antigen testing, microscopy, and individual real-time PCR) in
2014 yielded positive results for one or more GI pathogens in
only 8.5% and 2.7% of samples, respectively (unpublished
data).
In the above-mentioned prospective study at the Mayo Clinic
in Rochester MN, the FilmArray GI Panel identiﬁed mixed in-
fections in 21.1% of positive prospective samples, and routine
methods detected them in 8.3% [14]. In our European study,
the FilmArray GI Panel detected multiple organisms in 16.4% of
samples (representing 30% of positive samples), whereas
routine methods as applied by the participating laboratories
detected them in only 1% of samples. Our ﬁndings corroborateClinical Microbiology and Infection © 2015 The Authors. Published by Elsevier Ltd on behalf
This is an open access artithe suggestion of Khare et al. that the presence of multiple
pathogens in diarrhoeal stool samples is underestimated by
current routine tests [14].
EPEC or EAEC was present in 98 of 116 (84%) of our
EUCODI samples with multiple organism detection, which
raises the question of the clinical relevance of these putative
pathogens, or challenges the validity of the pathogen deﬁnitions
used. We believe that all of these EPEC and EAEC results could
require further investigation (e.g. serotyping of isolates). EPEC
and EAEC are not routinely tested for in most laboratories,
including the laboratories participating in EUCODI. In our
study, EPEC, Campylobacter, toxigenic C. difﬁcile, EAEC, nor-
ovirus and ETEC were the six most commonly detected
pathogens. Also at Mayo, EPEC topped the list, with EAEC again
being the fourth most commonly diagnosed potential agent
(EPEC, toxigenic C. difﬁcile, sapovirus, EAEC, norovirus,
Campylobacter, and ETEC) [14]. The high rate of EPEC and
EAEC detection in the stools of patients—but also in con-
trols—has previously been reported by others [15,16].
The EUCODI study conﬁrms that rotavirus and Salmonella
are no longer the leading viral and bacterial GI pathogens
(respectively) in Europe. Epidemiological studies have repeat-
edly reported changes in the prevalence rates of various caus-
ative agents in some European countries [5,6,8–10]. In Europe,
the inclusion of a childhood vaccine for rotavirus in national
immunization programmes (as recommended by the WHO
since 2009) and the legal obligation for member states to take
effective measures to control Salmonella in laying hen ﬂocksof European Society of Clinical Microbiology and Infectious Diseases, CMI, 21, 719–728
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community-acquired gastroenteritis during the last few years.
Presently, norovirus has been identiﬁed as the leading
cause of medically attended acute community-acquired
gastroenteritis in Europe; our ﬁnding is in accordance with
the situation in the USA [19]. However, both our data and the
ﬁndings from the Mayo study [14] also underscore that
rotavirus and sapovirus should also be part of the routine test
spectrum for community-acquired diarrhoea. In many labo-
ratories, ordering physicians must still speciﬁcally request
such testing. Leaving EPEC—which is currently not in the
diagnostic repertoire of most routine diagnostic labora-
tories—aside, our study suggests that Campylobacter and
toxigenic C. difﬁcile are the leading causes of community-
acquired bacterial enteritis in Europe, again in accordance
with the situation in the USA [14]. In our study, the high
C. difﬁcile prevalence in Romania does skew the frequency
distribution; however, if the Romanian cases are excluded,
C. difﬁcile is still the ﬁfth most frequently detected pathogen
(40, 17 of which were in multiple-pathogen samples), moving
it behind EAEC and norovirus in the ranking.
It is common practice at present to test for toxigenic
C. difﬁcile only in hospitalized patients or in those with other
risk factors, such as a history of recent antibiotic use or if other
testing gives negative results [1,2]. However, in the last decade,
there has also been a signiﬁcant increase in the detection of
community-acquired C. difﬁcile infection (CDI). Across Europe,
14% of CDI cases were found to be community associated in a
study in 2008 by Bauer et al. [20]. In a study on acute gastro-
enteritis in general practices in Austria in 2007, C. difﬁcile
accounted for 18.7% of positive results, as compared with 9.3%
for Campylobacter and 6.6% for Salmonella (norovirus, 36%;
rotavirus, 17.3%; and adenovirus, 5.4%) [10]. Considering the
importance of toxigenic C. difﬁcile, we conclude that labora-
tories should evaluate the need for routine toxigenic C. difﬁcile
testing of samples from patients with community-acquired
diarrhoea. In this context, we note that, in contrast to EPEC,
toxigenic C. difﬁcile is infrequently found in healthy adults
[21,22]. Current guidelines for the diagnosis of CDI state that
algorithm testing should be used, as stand-alone tests are not
suitable with regard to sensitivity/speciﬁcity, especially when
tests are performed in low-prevalence populations [23].
Community-acquired GI infections show a seasonal pattern.
The wintertime predominance of norovirus infection is so
marked that it has been called ‘winter-vomiting disease’. Cam-
pylobacteriosis and salmonellosis occur more commonly during
the summer [24]. Although our data show the descriptive
trends in absolute numbers noted in the literature, they do not
show statistically signiﬁcant variation (probably because of the
low sample size). However, this seasonality is insufﬁcientlyClinical Microbiology and Infection © 2015 The Authors. Published by Elsevier Ltd on behalf of
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licemarked to warrant seasonal omission of certain targets from
the test spectrum for community-acquired diarrhoea.
Some organisms may be carried asymptomatically. Detection
of organisms by conventional methods or by molecular
diagnostics may therefore not mean that the corresponding
organisms are responsible for a patient’s symptoms. The Fil-
mArray GI Panel and molecular diagnostics in general have
another inherent limitation: viral, bacterial and parasite nucleic
acid may persist in vivo, independently of organism viability [12].
Discrepancies between the FilmArray GI Panel and other mi-
crobial identiﬁcation methods may also be caused by the
inability to reliably differentiate species with standard pheno-
typic microbial identiﬁcation methods. Examples include the
differentiation of Y. enterocolitica from other Y. enterocolitica
group members, and the differentiation of E. histolytica from
Entamoeba dispar. There is also a risk of false-negative results
due to the presence of sequence variants in the gene targets of
the assay, procedural errors, or inadequate numbers of
organisms for ampliﬁcation. In our opinion, these inherent
limitations are far outweighed by the numerous advantages of
an automated multiplex PCR system. The relatively high rate of
failed attempts noted in our EUCODI study (4.8% of our tests
had to be repeated) was most likely due to the use of devel-
opmental pouches, and was higher than that reported during
the prospective clinical evaluation of the product by the
manufacturer (0.6%) [13].
With the exception of toxigenic C. difﬁcile and diarrhoeagenic
E. coli targets, the chosen gene targets are proprietary.
Although the published performance data substantiate the
appropriateness of the chosen targets [13,14], we feel that
operators of the FilmArray GI Panel should have access to such
details.
Our EUCODI study has clear limitations. The ﬁrst concerns
the representativeness: the participating laboratories were
chosen mainly because of their engagement in the ESCMID
Food- and Water-borne Infections Study Group. These labo-
ratories may not necessarily be representative of their country.
Similarly, the ten countries identiﬁed do not represent all
member states within the EU. Second, the number of samples
was rather low (n = 709), and its statistical power should be
interpreted with caution. Despite these limitations, we consider
that multicentre, cross-sectional point-prevalence studies of
community-acquired diarrhoea are suitable for generating valid,
up-to-date knowledge concerning the spectrum of possible
pathogens in acute community-acquired gastroenteritis in
Europe. We feel that our results call for a more comprehensive
comparative study, as this limited EUCODI study clearly shows
feasibility. Such a comprehensive comparative study would
allow a critical appraisal of the validity of information on
communicable GI diseases provided by ofﬁcial surveillanceEuropean Society of Clinical Microbiology and Infectious Diseases, CMI, 21, 719–728
nses/by-nc-nd/4.0/)
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routine laboratories, e.g. the 2014 Annual Epidemiological
Report of the European Centre for Disease Prevention and
Control [25] and the EU Summary Report on Zoonoses,
Zoonotic Agents and Food-Borne Outbreaks 2012 [26]. The
present lack of standardization of various diagnostic assays
deployed in European laboratories inevitably hampers such
reports, and makes any direct comparison between countries
impossible. According to the EU summary report, the country-
speciﬁc notiﬁcation rates of reported conﬁrmed cases of human
campylobacteriosis in the EU in 2012 were highest in the Czech
Republic, Slovakia, Luxembourg, and the UK (106–174 per
100 000 population), and lowest rates in Bulgaria, Latvia, Italy,
Poland, and Romania (<2 per 100 000 population) [26].
Whereas in 2012 (according to the EU summary report) the
ratios of conﬁrmed cases of campylobacteriosis in the UK and
Romania were 273 : 1, and 250 : 1, respectively (according to
the annual European Centre for Disease Prevention and Con-
trol epidemiological report) [25], our EUCODI study yielded a
ratio of 2 : 1 for Campylobacter-positive specimens (UK, 12 of
72 samples positive for Campylobacter; Romania, six of 80
samples positive for Campylobacter) in 2014.
We conclude that multiplex screening can optimize the yield
from stool examinations, can dramatically improve the timeli-
ness of diagnosis, and can facilitate comparison of results among
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